Skip to content
lifestyle.recentlegalnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Business Wire
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions
May 26, 2026
GMR Solutions Inc. Sets First Quarter 2026 Earnings Call
May 26, 2026
FS Launches 400G High-Speed Interconnect Solution for Scalable Cloud Data Center Networking
May 26, 2026
WellSky® Enhances Long-Term Care Solution With Its AI-Powered CareQueue Workflow to Drive Real-time Clinical Prioritization
May 26, 2026
Safepoint Holdings, Inc. Announces Launch of Initial Public Offering
May 26, 2026
IT TechPros Announces Team Expansion and Move to New 2,640 SqFt Facility
May 26, 2026
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 26, 2026
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 26, 2026
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 26, 2026
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 26, 2026
←
Previous Page
1
…
14
15
16
17
18
…
4,589
Next Page
→